Matthew Galsky Gives an Overview of Bladder Cancer

(1:35)

Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

(59)

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

(1:36)

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

(1:58)

മാരക രോഗങ്ങൾക്ക് വിട - ന്യൂട്രീഷൻ ചികിത്സയിലൂടെ അത്ഭുത രോഗശാന്തി EXCLUSIVE INTERVIEW DR.A.SREEKUMAR

(31:55)

കാൻസർ? പേടിക്കാതെ ജീവിക്കാം || cancer live without fear || EP 117

(59:12)

Cancer Treatment in CKD Patients - Prof. Dr. Sabine Karam, Prof. Dr. Jolanta Małyszko

(57:30)

Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023

(6:31)

Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response

(1:2:29)

อย่านิ่งนอนใจ! อาการเตือนโรคระบบทางเดินปัสสาวะ | บำรุงราษฎร์

(5:19)

How is Advanced Bladder Cancer Treated?

(6:46)

30% of stage 4 bladder cancer patients can now go on to live beyond five years: Dr. Shyam Aggarwal

(4:31)

Nivo+Gem/Cis Is Durable, Improves Survival in Patients With Lymph Node–Only mUC

(7:52)

Understanding Immunotherapy for Bladder Cancer

(7:37)

Bladder Cancer Immunotherapy: Building on a history of immune response

(26:56)

Dr. Galsky on the Role of Ipilimumab for the Treatment of Bladder Cancer

(1:20)

Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

(59)

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

(1:9)

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

(1:35)

Dr. Matthew Galsky - ASCO 2021

(4:22)

Dr. Galsky on Targeted Therapies in Bladder Cancer

(2:3)

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

(2:19)

Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer

(2:21)

Dr. Galsky on Ipilimumab in Bladder Cancer

(1:7)

Dr. Galsky Discusses a Biomarker Development Trial for Satraplatin in mCRPC

(1:40)

Breakthroughs in Bladder Cancer Immunotherapy, with Matthew Galsky

(44:28)

Dr. Galsky Discusses Progression in Patients With Metastatic Bladder Cancer

(2:25)

Dr. Galsky on Sequencing Questions in Urothelial Cancer

(1:20)

07 Immunotherapy for bladder cancer What is Standard and What is the future Prof M Galsky

(32:26)

Dr. Matthew Galsky on Fatal Adverse Events Associated With mTOR Inhibitors

(2:)